163 related articles for article (PubMed ID: 10688084)
1. Urinary NMP22 and renal cell carcinoma.
Huang S; Rhee E; Patel H; Park E; Kaswick J
Urology; 2000 Feb; 55(2):227-30. PubMed ID: 10688084
[TBL] [Abstract][Full Text] [Related]
2. Urinary nuclear matrix protein 22 for diagnosis of renal cell carcinoma.
Kaya K; Ayan S; Gokce G; Kilicarslan H; Yildiz E; Gultekin EY
Scand J Urol Nephrol; 2005; 39(1):25-9. PubMed ID: 15764267
[TBL] [Abstract][Full Text] [Related]
3. Value of urinary NMP-22 in patients with renal cell carcinoma.
Ozer G; Altinel M; Kocak B; Yazicioglu A; Gonenc F
Urology; 2002 Oct; 60(4):593-7. PubMed ID: 12385914
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the nuclear matrix protein 22 with voided urine cytology and BTA stat test in the diagnosis of transitional cell carcinoma of the bladder.
Sözen S; Biri H; Sinik Z; Küpeli B; Alkibay T; Bozkirli I
Eur Urol; 1999 Sep; 36(3):225-9. PubMed ID: 10450007
[TBL] [Abstract][Full Text] [Related]
5. NMP22 in transitional cell carcinoma of the urinary bladder.
Su CK; Yang CR; Horng YY; Kao YL; Ho HC; Ou YC; Cheng CL
J Chin Med Assoc; 2003 May; 66(5):294-8. PubMed ID: 12908572
[TBL] [Abstract][Full Text] [Related]
6. Use of a new tumor marker, urinary NMP22, in the detection of occult or rapidly recurring transitional cell carcinoma of the urinary tract following surgical treatment.
Soloway MS; Briggman V; Carpinito GA; Chodak GW; Church PA; Lamm DL; Lange P; Messing E; Pasciak RM; Reservitz GB; Rukstalis DB; Sarosdy MF; Stadler WM; Thiel RP; Hayden CL
J Urol; 1996 Aug; 156(2 Pt 1):363-7. PubMed ID: 8683680
[TBL] [Abstract][Full Text] [Related]
7. Exclusion criteria enhance the specificity and positive predictive value of NMP22 and BTA stat.
Sharma S; Zippe CD; Pandrangi L; Nelson D; Agarwal A
J Urol; 1999 Jul; 162(1):53-7. PubMed ID: 10379739
[TBL] [Abstract][Full Text] [Related]
8. Urinary dosage of nuclear matrix protein 22 (NMP22) like biologic marker of transitional cell carcinoma (TCC): a study on patients with hematuria.
Paoluzzi M; Cuttano MG; Mugnaini P; Salsano F; Giannotti P
Arch Ital Urol Androl; 1999 Feb; 71(1):13-8. PubMed ID: 10193018
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of NMP22 in the detection of transitional cell carcinoma of the bladder.
Stampfer DS; Carpinito GA; Rodriguez-Villanueva J; Willsey LW; Dinney CP; Grossman HB; Fritsche HA; McDougal WS
J Urol; 1998 Feb; 159(2):394-8. PubMed ID: 9649246
[TBL] [Abstract][Full Text] [Related]
10. [Urinary NMP22 as a new marker in patients with transitional cell carcinoma].
Muzzonigro G; Minardi D; Galosi AB; Recchioni A; De Sio G; Polito M
Arch Ital Urol Androl; 1999 Jun; 71(3):171-7. PubMed ID: 10431409
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of nuclear matrix protein 22 as a tumour marker in the detection of transitional cell carcinoma of the bladder.
Sánchez-Carbayo M; Herrero E; Megías J; Mira A; Soria F
BJU Int; 1999 Oct; 84(6):706-13. PubMed ID: 10510120
[TBL] [Abstract][Full Text] [Related]
12. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
Kelly JD; Dudderidge TJ; Wollenschlaeger A; Okoturo O; Burling K; Tulloch F; Halsall I; Prevost T; Prevost AT; Vasconcelos JC; Robson W; Leung HY; Vasdev N; Pickard RS; Williams GH; Stoeber K
PLoS One; 2012; 7(7):e40305. PubMed ID: 22792272
[TBL] [Abstract][Full Text] [Related]
13. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
14. The addition of urinary urokinase-type plasminogen activator to urinary nuclear matrix protein 22 and cytology improves the detection of bladder cancer.
Shariat SF; Casella R; Monoski MA; Sulser T; Gasser TC; Lerner SP
J Urol; 2003 Dec; 170(6 Pt 1):2244-7. PubMed ID: 14634389
[TBL] [Abstract][Full Text] [Related]
15. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
16. Urinary NMP22 for the detection of recurrence after transurethral resection of transitional cell carcinoma of the bladder: experience on 137 patients.
Serretta V; Lo Presti D; Vasile P; Gange E; Esposito E; Menozzi I
Urology; 1998 Nov; 52(5):793-6. PubMed ID: 9801101
[TBL] [Abstract][Full Text] [Related]
17. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--NMP22 as a urinary marker for surveillance of bladder cancer. NMP22 Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):829-36. PubMed ID: 9170521
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of urinary level of NMP22 as a diagnostic marker for stage pTa-pT1 bladder cancer: comparison with urinary cytology and BTA test.
Del Nero A; Esposito N; Currò A; Biasoni D; Montanari E; Mangiarotti B; Trinchieri A; Zanetti G; Serrago MP; Pisani E
Eur Urol; 1999 Feb; 35(2):93-7. PubMed ID: 9933801
[TBL] [Abstract][Full Text] [Related]
19. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the monoclonal UBC-ELISA test and the NMP22 ELISA test for the detection of urothelial cell carcinoma of the bladder.
Mian C; Lodde M; Haitel A; Vigl EE; Marberger M; Pycha A
Urology; 2000 Feb; 55(2):223-6. PubMed ID: 10688083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
